Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Varian (VAR) Hits A 52-Week High: What's Driving The Stock?

By Zacks Investment ResearchStock MarketsJan 09, 2020 05:52AM ET
www.investing.com/analysis/varian-var-hits-a-52week-high-whats-driving-the-stock-200497488
Varian (VAR) Hits A 52-Week High: What's Driving The Stock?
By Zacks Investment Research   |  Jan 09, 2020 05:52AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Shares of Varian (NYSE:VAR) scaled a new 52-week high of $147.06 on Jan 8, closing the session marginally lower at $146. In fact, the stock has rallied nearly 10.9% since its fourth-quarter fiscal 2019 earnings announcement on Nov 22.

Solid growth in core oncology segment, profitable acquisitions and a solid guidance for fiscal 2020 have prompted the rally.

Let us take a closer look at the factors driving growth.

Robust Q4 Earnings

The company exited the fourth quarter of fiscal 2019 on a promising note, with earnings meeting the Zacks Consensus Estimate and revenues surpassing the same. Revenues at the oncology segment rose 8.5% during the quarter driven by a surge in gross orders and expansion of net installed base.

Gross margin in the reported quarter was up 150 bps, while operating margin expanded 50 bps.

The lifted revenue outlook for fiscal 2020 buoys optimism among investors, indicating the continuation of this bullish trend through the year.

Other Encouraging Factors

Market has been upbeat about Varian’s recent acquisition of Cancer Treatment Services International. The collaboration is expected to boost Varian Medical’s core Oncology Systems business.

The company also recently announced an asset purchase agreement to acquire Boston Scientific’s portfolio of drug-loadable microsphere and bland embolic bead products for $90 million. This will strengthen Varian’s interventional oncology segment. Investors have also been optimistic about the company’s prospects since it announced the acquisitions of CyberHeart, Endocare and Alicon.

Meanwhile, Varian has been having a great run on the bourses in the past year. The stock has rallied 18.4% versus the broader industry’s growth of 14.8%. The company currently has a market cap of $13.29 billion.

Zacks Rank & Stocks Worth a Look

Varian currently carries a Zacks Rank #4 (Sell).

A few better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , West Pharmaceutical Services (NYSE:WST) and Omnicell (NASDAQ:OMCL) . While Haemonetics sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Haemonetics has a projected long-term earnings growth rate of 13.5%.

West Pharmaceutical Services has an expected long-term earnings growth rate of 14%.

Omnicell has a long-term earnings growth rate of 12.5%.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.

This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.

See their latest picks free >>



Omnicell, Inc. (OMCL): Free Stock Analysis Report

Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report

Haemonetics Corporation (HAE): Free Stock Analysis Report

West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report

Original post

Zacks Investment Research
Varian (VAR) Hits A 52-Week High: What's Driving The Stock?
 

Related Articles

Varian (VAR) Hits A 52-Week High: What's Driving The Stock?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email